France's Ipsen H1 revenue rises 20.4%, lifts 2026 outlook

Ipsen SA

30/07/2026 06:13

Overview
France biopharma firm's H1 revenue rose 20.4% yr/yr, driven by portfolio growth beyond Somatuline
Adjusted EBIT for H1 rose 28.8% yr/yr, with core operating margin up 2.5 points to 38.6%
Company raised FY 2026 guidance for sales growth and core operating margin

Outlook
Ipsen raises 2026 total sales growth guidance to above 20% at constant exchange rates
Company now sees 2026 core operating margin above 37% of total sales
Ipsen expects about 1% adverse currency impact on 2026 total sales based on June rates

Result Drivers
PORTFOLIO BEYOND SOMATULINE - Ipsen said sales growth was driven by acceleration in its portfolio beyond Somatuline, with all three therapeutic areas contributing
PIPELINE PROGRESS - Co cited positive Phase III readouts for Dysport in migraine and Iqirvo in primary biliary cholangitis as supporting growth and future launches
ACQUISITIONS - Recent and proposed acquisitions of Memo Therapeutics AG and Kartos Therapeutics added late-stage pipeline assets and supported growth outlook

Company press release: ID:nGNX9BrBh2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
Beat
EUR 2.19 bln
EUR 1.56 bln (2 Analysts)
H1 Adjusted EPS
 
EUR 7.33
 
H1 EPS
 
EUR 4.86
 
H1 Adjusted EBIT
Beat
EUR 844.90 mln
EUR 721 mln (1 Analyst)
H1 Adjusted EBIT Margin
 
38.60%
 
H1 EBIT
 
EUR 564.80 mln
 
H1 EBIT Margin
 
25.80%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ipsen SA is €170.00, about 3.8% above its July 29 closing price of €163.70
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 13 three months ago

Reuters Recommended Reads
July 29 - France's EuroAPI H1 net sales fall on product discontinuations
July 28 - GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs
July 29 - J&J lowers 2026 profit forecast on deal costs, sees further hit in 2027

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)